Rexinoid Compounds for Metabolic Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological strategies targeting nuclear receptors for cardiometabolic diseases, such as PPARγ agonists and rexinoids, have shown partial success but are limited by side effects like water retention, hepatotoxicity, and non-selective stimulation of RXR signaling, which affect their therapeutic index.
Innovation Solution
Development of a class of rexinoid compounds with specific structural formulas that act as agonists or antagonists, potentially offering improved therapeutic indices by providing glucose-lowering, insulin-sensitizing, and triglyceride-lowering effects without the adverse side effects associated with existing rexinoids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PPARγ agonists are used to treat metabolic disorders, then insulin sensitivity is improved, but water retention and heart failure occur
Solution Approach 1:
The patent applies parameter changes by developing rexinoid compounds with modified chemical structures (Formulas I, II, and III with various substituents R, R1, R2, R3, A, B, C, D) to alter the therapeutic profile. These structural modifications aim to achieve glucose-lowering and insulin-sensitizing effects while minimizing side effects like hepatomegaly and triglyceride elevation that occur with existing rexinoids.
2Reliability
If PPARγ agonists are used to treat metabolic disorders, then lipid levels are lowered, but hepatotoxicity and gallstone formation occur
Solution Approach 1:
The patent modifies the chemical parameters of rexinoid compounds through systematic structural variations (different R groups, ring structures, and substituents) to achieve optimal therapeutic index. The goal is to maintain lipid-lowering efficacy while reducing hepatotoxicity and gallstone formation risks associated with current PPARγ agonists.
3Reliability
If existing rexinoids are used to lower glucose and improve insulin sensitivity, then metabolic effects are beneficial, but dose-limiting side effects occur including elevation of serum triglyceride levels and hepatomegaly
Solution Approach 1:
The patent employs parameter changes by developing novel rexinoid compounds with specific structural formulas (I, II, and III) featuring varied substituents and ring structures. These modifications are designed to maintain beneficial glucose-lowering and insulin-sensitizing effects while eliminating dose-limiting side effects such as serum triglyceride elevation and hepatomegaly.
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and substituents at particular positions in the rexinoid molecular structure (R, R1, R2, R3, A, B, C, D positions). This localized structural modification allows selective enhancement of therapeutic effects while minimizing adverse effects on specific organs and metabolic parameters.
4Reliability
If existing rexinoids are used to treat metabolic syndrome, then glucose metabolism is improved, but non-selective stimulation of RXR signaling causes side effects
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substituents at particular positions in the rexinoid molecular structure (R, R1, R2, R3, A, B, C, D positions). This localized structural modification allows selective enhancement of therapeutic effects while minimizing adverse effects on specific organs and metabolic parameters.
Solution Approach 2:
The patent segments the RXR signaling pathway activation by designing compounds that can selectively activate specific RXR isoforms or tissue-specific RXR functions. The modular structural design (with variable R groups and ring structures) allows differential binding affinity to various RXR targets, achieving selective stimulation rather than blanket activation of all RXR signaling pathways.
Data Source
AI summary
Novel rexinoid compounds are provided herein. Also provided herein are methods of using the compounds to treat disorders, such as metabolic disorders, diabetes, insulin resistance, glucose intolerance, obesity, steatosis, inflammation, and/or cancer.